A whole new mushroom convoy pulls up to Parliament!

,
What’s happening at the Canadian Capital? Canadian non-profit organization TheraPsil is leading a delegation of patients, advocates & experts to return to Ottawa this February from the 11th-17th seeking compassionate access to psilocybin…
telesage

TeleSage Revolutionizes How We Assess The Benefits of Psychedelic Therapy

TeleSage uses the SAGE-SR protocol to offer holistic assessments essential for integrated psychedelic medicine
Compass Pathways Appoints a New CEO

Compass Pathways Appoints a New CEO

George Goldsmith will be replaced as Compass Pathways CEO. Is this good or bad news?

The Battle for Psychedelic Patents

Psychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP

Psychedelic Business Spotlight – July 1

,
This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with Wiz Khalifa; Field Trip shareholders approve company split; and more!

Wiz Khalifa Teams Up With Red Light Holland for Boutique Mushroom Brand

,
The rapper known for his cannabis advocacy has partnered with Red Light Holland to launch a mushroom wellness brand called MISTERCAP
Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld

Compass Pathways Psilocybin Patent Upheld

Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.
Psychedelic Business Spotlight - June 17

Psychedelic Business Spotlight – June 17

,
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
The Four Psychedelics ETFs Capturing Investor Attention

The Four Psychedelics ETFs Capturing Investor Attention

Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success will vary.